

Crk II (C-18): sc-289



The Power to Question

BACKGROUND

The Crk family of adapter proteins including Crk II, Crk I and Crk L consist mostly of SH2 and SH3 domains. Through the interactions between SH2 domain and phosphotyrosine residues and/or between SH3 domain and proline-rich motifs, they are involved in a variety of signaling cascades. Crk I and Crk II are encoded by the same gene, which undergoes alternative splicing to yield these two proteins, but differ in their biological activities. Crk II has less transforming activity than Crk I, although both Crk I and Crk II bind to many tyrosine-phosphorylated proteins that bind to GRB2. In addition, Crk II becomes rapidly tyrosine-phosphorylated in response to stimulation with Insulin-like growth factor-I (IGF-I) and might be involved in the IGF-I receptor signalling pathway. The gene encoding Crk I and II maps to human chromosome 17p13.3, a region which demonstrates frequent deletion or loss of heterozygosity in a wide range of human cancers.

CHROMOSOMAL LOCATION

Genetic locus: CRK (human) mapping to 17p13.3; Crk (mouse) mapping to 11 B5.

SOURCE

Crk II (C-18) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the C-terminus of Crk II of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-289 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

Crk II (C-18) is recommended for detection of Crk II p40 and p42 of mouse, rat, human and chicken origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Crk II (C-18) is also recommended for detection of Crk II p40 and p42 in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for Crk II siRNA (h): sc-37072, Crk II siRNA (m): sc-44854, Crk II shRNA Plasmid (h): sc-37072-SH, Crk II shRNA Plasmid (m): sc-44854-SH, Crk II shRNA (h) Lentiviral Particles: sc-37072-V and Crk II shRNA (m) Lentiviral Particles: sc-44854-V.

Molecular Weight of Crk II isoforms: 40/42 kDa.

Positive Controls: Crk II (m): 293T Lysate: sc-125171, HeLa whole cell lysate: sc-2200 or Crk II (h): 293 Lysate: sc-110474.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



Crk II (C-18): sc-289. Western blot analysis of Crk II expression in non-transfected: sc-117752 (A) and mouse Crk II transfected: sc-125171 (B) 293T whole cell lysates.



Crk II (C-18): sc-289. Western blot analysis of Crk II expression in non-transfected: sc-110760 (A) and human Crk II transfected: sc-110474 (B) 293 whole cell lysates.

SELECT PRODUCT CITATIONS

- Sutherland, C.L., et al. 1996. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. *J. Immunol.* 157: 3381-3390.
- Miller, C.T., et al. 2003. Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. *Oncogene* 22: 6006-6013.
- Cheng, C.H., et al. 2004. Blockade of v-Src-stimulated tumor formation by the Src homology 3 domain of Crk-associated substrate (Cas). *FEBS Lett.* 557: 221-227.
- Hartman, A.D., et al. 2006. Constitutive c-Jun N-terminal kinase activity in acute myeloid leukemia derives from Flt-3 and affects survival and proliferation. *Exp. Hematol.* 34: 1360-1376.
- Moon, A.M., et al. 2006. Crkl deficiency disrupts Fgf8 signaling in a mouse model of 22q11 deletion syndromes. *Development* 10: 71-80.
- Chan, P.C., et al. 2010. Differential phosphorylation of the docking protein Gab1 by c-Src and the hepatocyte growth factor receptor regulates different aspects of cell functions. *Oncogene* 29: 698-710.
- Hallock, P.T., et al. 2010. Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L. *Genes Dev.* 24: 2451-2461.
- Weber, A., et al. 2010. The TFIIH subunit p89 (XPB) localizes to the centrosome during mitosis. *Cell. Oncol.* 32: 121-130.
- Mortazavi, F., et al. 2011. c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells. *Clin. Exp. Metastasis* 28: 391-404.

MONOS
Satisfaction
Guaranteed

Try **Crk II (B-4): sc-390132** or **Crk I/II (D-6): sc-393160**, our highly recommended monoclonal alternatives to Crk II (C-18).